The Changes of Retinal Capillaries After Half-dose PDT Measured by OCTA in Eyes With CSC

checkorphan
Learn more about:
Central serous chorioretinopathy
Related Clinical Trial
Eplerenone Versus PDT: Comparative Study by OCTA Pilot Study on Deep Learning in the Eye Panmacular Versus Minimal Micropulse Laser Therapy in Central Serous Chorioretinopathy OCT in Rare Chorioretinal Diseases Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO Selective RPE Laser Treatment (SRT) for Various Macular Diseases Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina Non-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC) Eye Patch Therapy for Central Serous Retinopathy (CSR) Multimodal Imaging in Central Serous Chorioretinopathy PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept Microperimetric Evaluation After Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy Pseudo-PDT in Central Serous Chorioretinopathy Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC) Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC) Selective Retina Therapy With Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients Selective Retina Therapy (SRT) in Patients With Idiopathic Central Serous Retinopathy Effects of OCTA-guided PDT in Acute CSC Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy Photodynamic Therapy Versus Eplerenone: Treatment Trial for Chronic Central Serous Chorioretinopathy Micropulse 577nm Laser vs Traditional Laser Treatment in Central Serous Chorioretinopathy The Changes of Retinal Capillaries After Half-dose PDT Measured by OCTA in Eyes With CSC Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy Treatment Trial for Acute Central Serous Chorioretinopathy The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole Selective Retina Therapy With ‘R:GEN’ in Patients With Central Serous Chorioretinopathy 577nm Micropulse Laser vs Half-dose Photodynamic Therapy on Acute Central Serous Chorioretinopathy Central Serous Chorioretinopathy: Etiology, Course and Prognosis A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Treatment of Chronic Central Serous Chorioretinopathy Via Electromagnetic Stimulation and Platelet- Rich Plasma Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy The Effect of Therapy With Bevacizumab in Chronic Central Serous Chorioretinopathy Eplerenone for the Treatment of Central Serous Chorioretinopathy Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy Comparison of Multifocal Electroretinogram Assessment in Chronic Central Serous Chorioretinopathy (CSC) Between Laser Treatment Group and Photodynamic Therapy Group in Chronic Central Serous Chorioretinopathy Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy Optical Coherence Tomography Angiography (OCT-A) and Central Serous Chorioretinopathy (CSC) Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy Effect of Helicobacter Pylori Treatment on Idiopathic Central Serous Chorioretinopathy (ICSCR) Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate Short-Term Oral Mifepristone for Central Serous Chorioretinopathy Methotrexate for Central Serous Chorioretinopathy Treatment Trial Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Eplerenone for Central Serous Chorioretinopathy High-dose Antioxidants for Central Serous Chorioretinopathy

Brief Title

The Changes of Retinal Capillaries After Half-dose PDT Measured by OCTA in Eyes With CSC

Official Title

The Changes of Retinal and Choroidal Capillaries After Half-dose Photodynamic Therapy Measured by Angio- OCT in Eyes With Central Serous Chorioretinopathy

Brief Summary

      To determine changes in retinal and choroidal capillaries with optical coherence tomographic
      angiography (OCTA) after half-dose photodynamic therapy (hd-PDT) in eyes with central serous
      chorioretinopathy (CSC).

Detailed Description

      PDT was hypothesized to have a primary effect on the choroidal capillaries, and a number of
      studies have reported choriocapillary damage and choroidal vascular remodeling after PDT.
      More recently, although OCTA related CSC research has been conducted, no quantitative report
      has thoroughly investigated the microstructural changes in the superficial, deep retinal and
      choroidal capillaries after hd-PDT. The purpose of the present study is to determine the
      changes in the retinal and choroidal capillaries quantitatively with OCTA after hd-PDT in
      eyes with CSC.

      This is a prospective observational study of patients undergoing hd-PDT for CSC with active
      leakage in retinal pigment epithelium (RPE) and followed for 3 months. Fundus fluorescein
      angiography (FFA) and indocyanine green angiography (ICGA) were performed at baseline; best
      corrected visual acuity (BCVA), fundus photography, optical coherence tomography angiography
      (OCTA) with the split-spectrum amplitude-decorrelation angiography algorithm (XR Optovue,
      Fremont, CA, USA) and spectral domain OCT (SD-OCT) were performed at baseline and each
      follow-up visit after hd-PDT.

Study Type

Observational

Primary Outcome

Changes of retinal capillaries after hd-PDT

Secondary Outcome

 The proportion of eyes with complete absorption of subretinal fluid(SRF)

Condition

Central Serous Chorioretinopathy

Intervention

Half-dose photodynamic therapy

Study Arms / Comparison Groups

 CSC patients
Description:  Half-dose photodynamic therapy was performed when a serous retinal detachment involving the macular fovea was present; The treatment field size was set as 3000 microns. This was achieved by administering 3mg/m² of Verteporfin intravenously over a period of 10 minutes. Fifteen minutes after commencing the verteporfin infusion the GLD was exposed to a 689 nm laser light with a florescence of 600 mw/cm² for 83 seconds and a total energy of 50 J/cm². OCTA (XR Optovue, Fremont, CA, USA) and spectral domain OCT (SD-OCT) were performed at baseline and each follow-up (one month and three months) visit after hd-PDT.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Procedure

Estimated Enrollment

60

Start Date

October 31, 2016

Completion Date

June 30, 2019

Primary Completion Date

October 10, 2018

Eligibility Criteria

        Inclusion Criteria:

          1. CSC diagnosed by FFA and ICGA, where the active leakage was just located in macular
             fovea with SRF confirmed by OCT

          2. Patient age ≥18 years

          3. BCVA ≥35 letters on ETDRS charts

          4. Persistent CSC for a period of time or patients were anxiety about the symptom and
             asking for treatment

          5. Lack of either spontaneous improvement or improvement induced by empirical treatment
             such as pharmaceutical drug

          6. The provision of written informed consent -

        Exclusion Criteria:

          1. The presence of any other chorioretinal diseases that may affect the studies, such as
             age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV)

          2. Patients who had received any previous treatment, including PDT, intraocular drug
             injection or focal thermal laser photocoagulation for CSC

          3. Patients with PED in macular fovea which the average diameter (transverse diameter and
             vertical diameter) was more than 300 microns

          4. Patients with high myopia, defined as a refractive error (spherical equivalent) <
             -6.00 diopters, or an axial length >26.5 mm

          5. Patients with media opacities, or signal strength index of the images < 60

          6. Patients under corticosteroid therapy -

Gender

All

Ages

18 Years - 65 Years

Contacts

Chenjin Jin, 15521250400, [email protected]

Location Countries

China

Location Countries

China

Administrative Informations

NCT ID

NCT03692169

Organization ID

CSC-PDT-OCTA（ZOC）

Responsible Party

Sponsor-Investigator

Study Sponsor

Jin Chen-jin

Study Sponsor

Chenjin Jin, Study Director, Zhongshan Ophthalmic Center, Sun Yat-sen University

Verification Date

September 2018